Market research
VXRT Vaxart Inc
PINK USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 110M
- P/E ratio
- 2.65
- Analyst target
- 3.3333
- Dividend yield
- Not available
- Beta
- 1.06
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 110M
- P/E ratio
- 2.65
- Analyst target
- 3.3333
- Dividend yield
- Not available
- Beta
- 1.06
About
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Research context
Vaxart Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VXRT discussion.
5 years, 6 months ago
Vaxart, Inc is currently in a long term uptrend where the price is trading 5.1% above its 200 day moving average.
From a valuation standpoint, the stock is 90.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 126.1.
Vaxart, Inc's total revenue sank by 99.9% to $4K since the same quarter in the previous year.
Its net income has increased by 100.0% to $-32 since the same quarter in the previous year.
Finally, its free cash flow fell by 206.7% to $-12M since the same quarter in the previous year.
Based on the above factors, Vaxart, Inc gets an overall score of 3/5.